Oocyst-Derived Extract of Toxoplasma Gondii Serves as Potent Immunomodulator in a Mouse Model of Birch Pollen Allergy

Abstract

IntroductionPreviously, we have shown that oral infection with Toxoplasma gondii oocysts prevented type I allergy in mice. Here we investigated whether the application of a T. gondii oocyst lysate antigen (OLA) could also reduce allergy development. BALB/c mice were immunised twice with OLA followed by sensitisation with the major birch pollen (BP) allergen Bet v 1 and an aerosol challenge with BP extract.MethodsFirst, we tested OLA in vitro. Stimulation of splenocytes and bone marrow-derived dendritic cells (BMDC) with OLA led to the production of pro-inflammatory and regulatory cytokines such as IL-6, IFN-γ and IL-10. Moreover, BMDC exposed to OLA upregulated the maturation markers CD40, CD80, CD86, and MHCII. Furthermore, OLA was recognised by TLR2-transfected human embryonic kidney cells.ResultsImmunisation of mice with OLA induced high levels of Toxoplasma-specific IgG antibodies in sera along with increased production of IFN-γ and IL-10 in Toxoplasma-antigen restimulated splenocytes. OLA reduced allergic airway inflammation as manifested by significant reduction of eosinophils in bronchoalveolar fluids, decreased cellular infiltrates and mucus production in the lungs. Accordingly, Bet v 1-specific IgE was decreased in OLA-pretreated mice. The reduced allergic immune responses were accompanied by increased numbers of CD4+CD25highFoxp3+ regulatory T cells in spleens as well as by increased numbers of granulocytic myeloid-derived suppressor cells in lungs when compared to sensitised controls suggesting that these two cell populations might be involved in the suppression of the allergic immune responses.ConclusionOur data demonstrate that pretreatment with the oocyst extract can exert anti-allergic effects comparable to T. gondii infection. Thus, the immunomodulatory properties of the parasite extract indicate that this extract and in the future defined molecules thereof might serve as immunomodulatory adjuvants in allergy treatment and prophylaxis.

Toxoplasma gondii tachyzoite-extract acts as a potent immunomodulator against allergic sensitization and airway inflammation

“…gondii infection, as well as inactivated extract of T . gondii oocysts prevented the development of airway inflammation in a mouse model of birch pollen allergy 24 , 26 . Similarly, Fenoy et al .…”

“…gondii , but also the treatment with crude extract derived from T . gondii oocysts (OLA) can reduce the development of allergic responses in a mouse model of birch pollen allergy 26 . However, the collection of T .…”

Genetic analyses of Chinese isolates of Toxoplasma gondii reveal a new genotype with high virulence to murine hosts

“…The mouse model is a classical assay for presenting the cyst-forming capability of T. gondii strains (Wagner et al, 2016;Mahmoudv et al, 2016). In consideration of the great differences between mouse models and human clinical symptoms, the rat model has been suggested as a better analogy (Darcy and Zenner, 1993;Santoro et al, 1987).…”

MDSCs in infectious diseases: regulation, roles, and readjustment

“…Some of these effects are independent of TLR4 and Th2-type cytokines (18,19). Moreover, immunization of mice with Toxoplasma gondii (T. gondii) oocyst lysate antigen leads to increased numbers of PMN-MDSC in the lungs (20). However, the host sensors controlling MDSC accumulation in parasitic infections remain to be unveiled.…”